Ginger as a treatment for breast cancer
the ONA take:
Research published in the Journal of Biomedicine and Biotechnology suggests that ginger may be a promising breast cancer treatment. Researchers discovered an a chemical extract from Zingiber officinale, the medicinal plant ginger, that halted the proliferation of breast cancer cells without affecting normal breast cancer cells. This property, known as selective cytotoxicity, is highly significant.
Despite numerous therapies available, including tamoxifen and other selective estrogen receptor modulators, to fight breast cancer, breast cancer remains the most common type of cancer and the leading cause of death among women. In addition, despite an initial response to chemotherapy, breast cancer cells often survive and form resistance to treatment. About 40% of women treated with tamoxifen and almost all patients with metastatic disease experience relapse that leads to death.
Breast cancer is not the first to be susceptible to ginger; colorectal, liver, lung, pancreatic, skin, and prostate cancers have also been shown to be inhibited by ginger. If proven, ginger would be a low-cost option for cancer treatment when compared to drugs currently on the market.

Ginger as a treatment for breast cancer
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
- Elderly Patients Are Underrepresented in Trials For Soft Tissue Sarcoma
- Combination Effective as First-Line Therapy in Advanced ER-Positive HER2-Negative Breast Cancer
- In Older Women With Breast Cancer QoL May Predict 10-Year Mortality
- Screening Colonoscopy Improves CRC-Related Mortality in Veterans
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |